15 completed, 10 recruiting, 9 terminated, 8 unknown. 49 Phase 3, 15 Phase 2.
Follow Cannabidiol: new trials by email Literature Review of Cannabidiol trials Research Report on Cannabidiol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stratification and Treatment in Early Psychosis Study - PROMOTE Cannabidiol (CBD), Placebo - Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis | Phase 3 | Not yet recruiting | University of Oxford | 586 | 2026-12-01 | 2026-10-08 |
| Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving Cannabidiol (CBD), Placebo - Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 105 | 2026-10-21 | 2026-11-03 |
| Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol - Opioid Use Disorder | Phase 3 | Not yet recruiting | Montefiore Medical Center | 40 | 2026-10-01 | 2026-06-09 |
| Study of Cannabidiol in Sanfilippo Syndrome Epidiolex, Placebo - Sanfilippo Syndrome, Mucopolysaccharidosis III | Phase 2 / Phase 3 | Recruiting | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 35 | 2026-04-01 | 2026-09-15 |
| Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma 10% urea lotion plus 1% cannabidiol, Control - Mediciine, Systemic Sclerosis (SSc) | Phase 3 | Recruiting | Khon Kaen University | 36 | 2025-11-05 | 2025-11-24 |
| Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder Low-Dose Cannabidiol, Placebo Matched to Moderate-Dose Cannabidiol, Moderate-Dose Cannabidiol - Generalized Anxiety Disorder (GAD), Anxiety Disorders | Phase 3 | Recruiting | Wayne State University | 90 | 2025-11-03 | 2026-10-21 |
| Adjunctive Cannabidiol for Recovery From Opioid Study Cannabidiol, Placebo - Opioid Use Disorder (OUD) | Phase 3 | Recruiting | Icahn School of Medicine at Mount Sinai | 450 | 2025-06-13 | 2026-10-01 |
| Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials Cannabidiol (CBD) oral solution, Placebo - Refractory Epilepsy in Children, Refractory Epilepsy | Phase 3 | Recruiting | UMC Utrecht | 50 | 2025-02-06 | 2026-06-25 |
| Cannabidiol's Role in Dementia Management Cannabidiol Oil - Dementia, Vascular, Dementia, Mixed | Phase 2 / Phase 3 | Unknown | Hospital Pengajar Universiti Putra Malaysia | 486 | 2024-09-01 | 2024-07-23 |
| Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia Cannabidiol (CBD) Capsule 75mg, Placebo - Insomnia | Phase 3 | Active not recruiting | Avecho Biotechnology | 519 | 2024-05-16 | 2026-06-30 |
| Therapy With Paravertebral Oxygen-ozone Injections and Topical Cannabidiol and β-Caryophyllene Patch in Neck Pain Cannabidiol and β-Caryophyllene Patch, Oxygen-Ozone Therapy - Neck Pain | Phase 3 | Unknown | Humanitas Clinical and Research Center | 52 | 2024-02-01 | 2023-12-13 |
| Cannabidiol for Bipolar Depression (CBD-BD) Cannabidiol, Placebo - Bipolar Disorder | Phase 3 | Recruiting | University of British Columbia | 360 | 2023-10-15 | 2025-04-23 |
| Alcohol Use Disorder and Cannabidiol Cannabidiol, Placebo - Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | University of Colorado, Denver | 180 | 2023-04-30 | 2026-06-15 |
| Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures GWP42003-P, Placebo - Seizures Associated With EMAS | Phase 3 | Terminated | Jazz Pharmaceuticals | 3 | 2022-10-31 | 2025-02-03 |
| Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine - Placebo oral drops, Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg - Chronic Migraine, Headache, Overuse Headache Medication | Phase 2 / Phase 3 | Terminated | Hospital Israelita Albert Einstein | 110 | 2022-10-18 | 2025-02-24 |
| Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis Cannabidiol (CBD), Placebo - Knee Arthritis | Phase 2 / Phase 3 | Recruiting | NYU Langone Health | 100 | 2022-06-22 | 2026-06-09 |
| Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis Cannabidiol oral solution - Early Psychosis | Phase 3 | Recruiting | University of California, San Diego | 120 | 2022-06-01 | 2026-01-08 |
| CBD (Cannabidiol)/THC (Tetrahydrocannabinol) Solution as a Pharmacological Strategy for Patients With Fibromyalgia (FibroCann) cannabidiol and tetrahydrocannabinol, Placebo - Fibromyalgia | Phase 2 / Phase 3 | Unknown | FG Brasil LTDA | 40 | 2022-04-15 | 2022-04-11 |
| Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Cannabidiol (CBD) Oil Capsules, Sunflower Lecithin Oil in Capsule - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Unknown | McMaster University | 50 | 2021-12-15 | 2023-02-14 |
| Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. All trans-retinoic acid, 13-Cis Retinoic Acid plus Tocopherol, Mifepristone - Breast Cancer Female | Phase 3 | Unknown | Mahmoud Ramadan mohamed Elkazzaz | 160 | 2021-08-01 | 2021-08-23 |
Showing 20 of 49. Sign in to see all of them.
Epilepsy (9) · Epilepsies, Myoclonic (8) · Lennox Gastaut Syndrome (7) · Seizures (5) · Marijuana Abuse (4) · Spasms, Infantile (4) · Tuberous Sclerosis (3) · Alcoholism (2) · Anxiety Disorders (2) · Bipolar Disorder (2) · COVID-19 (2) · Fibromyalgia (2) · Generalized Anxiety Disorder (2) · Opioid-Related Disorders (2) · Psychotic Disorders (2)
Jazz Pharmaceuticals (12) · INSYS Therapeutics Inc (3) · University of Sao Paulo (2) · Antonio Waldo Zuardi (1) · Avecho Biotechnology (1) · Cardiol Therapeutics Inc. (1) · Colorado State University (1) · FG Brasil LTDA (1) · GW Research Ltd (1) · Hospital Israelita Albert Einstein (1) · Hospital Pengajar Universiti Putra Malaysia (1) · Hospital de Clinicas de Porto Alegre (1) · Humanitas Clinical and Research Center (1) · Icahn School of Medicine at Mount Sinai (1) · Johns Hopkins University (1)
United States (27) · Spain (7) · Brazil (6) · Italy (6) · Poland (6) · United Kingdom (6) · Netherlands (5) · Australia (4) · Canada (4) · France (2) · Austria (1) · Denmark (1) · Finland (1) · Germany (1) · Greece (1)
Neha Parikh (3) · Alexandre O Kaup, MD, PhD (1) · Ammaar H Abidi, DDS, PhD (1) · Amr Ahmed (1) · Christine Rabinak, PhD, MBA (1) · Cristiano Sconza, MD (1) · Darren Mansfield (1) · David Woliinsky, MD (1) · Deepika Slawek, MD, MPH, MS (1) · Dennis McNamara, MD (1) · Hilary Marusak, PhD (1) · Jose A. Crippa, MD; PhD (1) · Karen J Derefinko, PhD (1) · Karen Stern, MD (1)
PMID 29768152, PMID 33797076, PMID 33825230, PMID 34265088, PMID 34957550, PMID 37052803, PMID 40775196, PMID 28538134, PMID 30955420, PMID 32119035, PMID 33346789, PMID 34287833, PMID 34387679, PMID 34406656, PMID 34619044, PMID 35175622, PMID 37606606, PMID 37920963, PMID 38037108, PMID 38441854, PMID 40846590
2014 (5), 2015 (4), 2019 (2), 2018 (1), 2023 (1), 2025 (1), R01AA029606 (1), R34DA063987 (1), R61MH137105 (1), UH3DA050323 (1)